Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.17
At close: May 21 EDT
$1.23
0.064.97%
Pre-Market: 7:43 PM EDT
Comments
Loading...
Fate Therapeutics Analyst Ratings and Price Targets | NASDAQ:FATE | Benzinga
Fate Therapeutics Inc has a consensus price target of $6.21 based on the ratings of 23 analysts. The high is $10 issued by EF Hutton on August 9, 2023. The low is $2 issued by Barclays on May 14, 2025. The 3 most-recent analyst ratings were released by Barclays, Baird, and Stifel on May 14, 2025, May 14, 2025, and March 6, 2025, respectively. With an average price target of $3 between Barclays, Baird, and Stifel, there's an implied 144.26% upside for Fate Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Baird
Stifel
Wedbush
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Fate Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 62.84% | Barclays | Peter Lawson42% | $10 → $2 | Maintains | Overweight | Get Alert |
| 05/14/2025 | Buy Now | 225.68% | Baird | Jack Allen 35% | $5 → $4 | Maintains | Neutral | Get Alert |
| 05/14/2025 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | Hold → Hold | Get Alert |
| 03/06/2025 | Buy Now | 144.26% | Stifel | Benjamin Burnett44% | $5 → $3 | Maintains | Hold | Get Alert |
| 03/06/2025 | Buy Now | 307.1% | Wedbush | David Nierengarten58% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 03/06/2025 | Buy Now | 225.68% | Wells Fargo | Yanan Zhu40% | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 03/06/2025 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | Hold → Hold | Get Alert |
| 11/19/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 11/13/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 08/22/2024 | Buy Now | 307.1% | HC Wainwright & Co. | Raghuram Selvaraju42% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/14/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 06/17/2024 | Buy Now | 388.52% | Piper Sandler | Edward Tenthoff50% | $4 → $6 | Upgrade | Neutral → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 307.1% | HC Wainwright & Co. | Raghuram Selvaraju42% | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 632.78% | Canaccord Genuity | Bill Maughan19% | $11 → $9 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 388.52% | BMO Capital | Etzer Darout44% | $7 → $6 | Maintains | Market Perform | Get Alert |
| 05/10/2024 | Buy Now | 307.1% | Wedbush | David Nierengarten58% | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 225.68% | Piper Sandler | Edward Tenthoff50% | $7 → $4 | Maintains | Neutral | Get Alert |
| 05/06/2024 | Buy Now | 469.94% | Wedbush | David Nierengarten58% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/23/2024 | Buy Now | 469.94% | Wedbush | David Nierengarten58% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Gil Blum49% | — | Reiterates | → Hold | Get Alert |
| 03/28/2024 | Buy Now | 388.52% | B of A Securities | Tazeen Ahmad54% | $2 → $6 | Maintains | Underperform | Get Alert |
| 03/19/2024 | Buy Now | 469.94% | HC Wainwright & Co. | Raghuram Selvaraju42% | $7 → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 02/27/2024 | Buy Now | 469.94% | Morgan Stanley | Michael Ulz63% | $3 → $7 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 469.94% | BMO Capital | Etzer Darout44% | $6 → $7 | Maintains | Market Perform | Get Alert |
| 02/27/2024 | Buy Now | 714.2% | Barclays | Peter Lawson42% | $6 → $10 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 469.94% | Wedbush | David Nierengarten58% | $3 → $7 | Maintains | Neutral | Get Alert |
| 02/27/2024 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Reiterates | Perform → Perform | Get Alert |
| 11/20/2023 | Buy Now | 551.36% | Mizuho | Mara Goldstein56% | $12 → $8 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | 144.26% | Morgan Stanley | Michael Ulz63% | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2023 | Buy Now | 388.52% | BMO Capital | Etzer Darout44% | $5.4 → $6 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | Buy Now | 144.26% | Wedbush | David Nierengarten58% | $6 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 307.1% | Wells Fargo | Yanan Zhu40% | $6 → $5 | Maintains | Equal-Weight | Get Alert |
| 09/07/2023 | Buy Now | 307.1% | Cantor Fitzgerald | Li Watsek40% | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/16/2023 | Buy Now | 469.94% | Truist Securities | Robyn Karnauskas53% | → $7 | Reiterates | Hold → Hold | Get Alert |
| 08/10/2023 | Buy Now | 307.1% | Morgan Stanley | Michael Ulz63% | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | Buy Now | 388.52% | Barclays | Peter Lawson42% | $12 → $6 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 339.67% | BMO Capital | Etzer Darout44% | $6 → $5.4 | Maintains | Market Perform | Get Alert |
| 08/09/2023 | Buy Now | 714.2% | EF Hutton | Tony Butler42% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 469.94% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $7 | Reiterates | → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 307.1% | Stifel | Benjamin Burnett44% | $5.3 → $5 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | 307.1% | Cantor Fitzgerald | Li Watsek40% | $8 → $5 | Maintains | Neutral | Get Alert |
| 03/27/2023 | Buy Now | 388.52% | Wells Fargo | Yanan Zhu40% | → $6 | Assumes | → Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 714.2% | Citigroup | Yigal Nochomovitz53% | $9 → $10 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 714.2% | EF Hutton | Tony Butler42% | → $10 | Reiterates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 469.94% | HC Wainwright & Co. | Robert Burns43% | $115 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 01/09/2023 | Buy Now | 225.68% | Goldman Sachs | Andrea Tan37% | $10 → $4 | Maintains | Sell | Get Alert |
| 01/06/2023 | Buy Now | 551.36% | Morgan Stanley | Michael Ulz63% | $35 → $8 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | Buy Now | 225.68% | B of A Securities | Tazeen Ahmad54% | $72 → $4 | Downgrade | Buy → Underperform | Get Alert |
| 01/06/2023 | Buy Now | 331.53% | Stifel | Benjamin Burnett44% | $107 → $5.3 | Downgrade | Buy → Hold | Get Alert |
| 01/06/2023 | Buy Now | 714.2% | EF Hutton | Tony Butler42% | $16 → $10 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | 469.94% | Wedbush | David Nierengarten58% | → $7 | Downgrade | Outperform → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 714.2% | SVB Leerink | Daina Graybosch42% | $62 → $10 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren45% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 877.04% | Piper Sandler | Edward Tenthoff50% | $71 → $12 | Downgrade | Overweight → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 469.94% | BMO Capital | Etzer Darout44% | $20 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 469.94% | Truist Securities | Robyn Karnauskas53% | $46 → $7 | Downgrade | Buy → Hold | Get Alert |
| 01/05/2023 | Buy Now | 1202.72% | EF Hutton | Tony Butler42% | → $16 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | — | Guggenheim | Michael Schmitz44% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/22/2022 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Downgrade | Outperform → Perform | Get Alert |
| 12/15/2022 | Buy Now | 714.2% | Goldman Sachs | Andrea Tan37% | → $10 | Initiates | → Sell | Get Alert |
| 12/13/2022 | Buy Now | 3645.32% | Truist Securities | Robyn Karnauskas53% | $51 → $46 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | 4948.04% | SVB Leerink | Daina Graybosch42% | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | 6413.6% | Citigroup | Yigal Nochomovitz53% | $87 → $80 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 3563.9% | Cantor Fitzgerald | Li Watsek40% | $98 → $45 | Assumes | → Overweight | Get Alert |
| 09/09/2022 | Buy Now | 2749.7% | Morgan Stanley | Michael Ulz63% | $45 → $35 | Maintains | Equal-Weight | Get Alert |
| 07/28/2022 | Buy Now | — | Needham | Gil Blum49% | — | Initiates | → Hold | Get Alert |
| 07/12/2022 | Buy Now | 3726.74% | BMO Capital | Etzer Darout44% | $50 → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/11/2022 | Buy Now | 3726.74% | BMO Capital | Etzer Darout44% | → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 06/03/2022 | Buy Now | 2179.76% | Baird | Jack Allen 35% | → $28 | Initiates | → Neutral | Get Alert |
| 05/23/2022 | Buy Now | 5680.82% | Piper Sandler | Edward Tenthoff50% | $113 → $71 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Fate Therapeutics (FATE) stock?
The latest price target for Fate Therapeutics (NASDAQ:FATE) was reported by Barclays on May 14, 2025. The analyst firm set a price target for $2.00 expecting FATE to rise to within 12 months (a possible 62.84% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fate Therapeutics (FATE)?
The latest analyst rating for Fate Therapeutics (NASDAQ:FATE) was provided by Barclays, and Fate Therapeutics maintained their overweight rating.
When was the last upgrade for Fate Therapeutics (FATE)?
The last upgrade for Fate Therapeutics Inc happened on June 17, 2024 when Piper Sandler raised their price target to $6. Piper Sandler previously had a neutral for Fate Therapeutics Inc.
When was the last downgrade for Fate Therapeutics (FATE)?
The last downgrade for Fate Therapeutics Inc happened on January 24, 2023 when HC Wainwright & Co. changed their price target from $115 to $7 for Fate Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fate Therapeutics (FATE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fate Therapeutics was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Fate Therapeutics (FATE) correct?
While ratings are subjective and will change, the latest Fate Therapeutics (FATE) rating was a maintained with a price target of $10.00 to $2.00. The current price Fate Therapeutics (FATE) is trading at is $1.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
